Sarepta Therapeutics,, Inc. Common Stock (SRPT) Financials
Key financial figures for Sarepta Therapeutics,, Inc. Common Stock (Q2 2026).
Sarepta Therapeutics,, Inc. reported revenue of $401.3 million for Q2 FY2026, down 34.3% from the same period a year earlier. The company posted a net loss of $4.9 million, or -$0.05 per share. Operating margin came to 3.31%, against 18.91% a year earlier. Free cash flow for the period was -$8.2 million. Across the last 5 reported quarters, quarterly revenue has moved from $611.1 million in Q2 FY2025 to $401.3 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Sarepta Therapeutics,, Inc. are on the SentiSense financials page.
- Revenue
- $401M
- Net Income
- -$5M
- EPS
- $-0.05
- Total Assets
- $3.2B
- Operating Cash Flow
- -$6M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $401M | -$5M | -$0.05 | 3.31% | -$8M |
| Q1 FY2026 | $731M | $331M | $2.88 | 49.05% | -$206M |
| Q4 FY2025 | $443M | -$283M | -$3.93 | -92.92% | $125M |
| Q3 FY2025 | $399M | -$180M | -$1.80 | -25.89% | -$43M |
| Q2 FY2025 | $611M | $197M | $1.89 | 18.91% | $229M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2.2B | -$713M | -$7.13 | -29.92% | -$307M |
| FY2024 | $1.9B | $235M | $2.34 | 11.47% | -$353M |
| FY2023 | $1.2B | -$536M | -$5.80 | -21.54% | -$588M |
Frequently asked questions
What was Sarepta Therapeutics,, Inc.'s revenue last quarter?
Sarepta Therapeutics,, Inc. reported revenue of $401.3 million for Q2 FY2026, down 34.3% from the same period a year earlier.
Is Sarepta Therapeutics,, Inc. profitable?
Not in its most recent reported period. Sarepta Therapeutics,, Inc. reported a net loss of $4.9 million for Q2 FY2026, a net margin of -1.22% on revenue.
How has Sarepta Therapeutics,, Inc.'s margin trended?
Operating margin was 3.31% in Q2 FY2026, compared with 18.91% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Sarepta Therapeutics,, Inc. generate?
Sarepta Therapeutics,, Inc. generated free cash flow of -$8.2 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Sarepta Therapeutics,, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.